Rationale: Treatment-resistant post-traumatic stress disorder (TR-PTSD) remains a significant clinical challenge despite the availability of evidence-based psychotherapies and first-line pharmacologic treatments. 3,4-Methylenedioxymethamphetamine–assisted psychotherapy (MDMA-AP) has emerged as a potential intervention because of its unique neuropsychological effects, including enhanced emotional processing and attenuation of fear responses.
Objective: This scoping review’s objective is to map the clinical data surrounding MDMA-AP for TR-PTSD. Although several early-phase clinical trials have evaluated MDMA-AP, the existing evidence has not been comprehensively mapped with respect to dosing strategies, psychotherapy structure, safety, and long-term outcomes.
Methods: This scoping review followed PRISMA-ScR guidelines. A systematic search of PubMed, Embase, Cochrane Library, and ScienceDirect databases revealed studies published between January 2010 and January 2025. Eligible studies included original clinical research evaluating MDMA-AP in adults with TR-PTSD. Six studies ultimately met the inclusion criteria. Data were charted for study design, participant characteristics, dosing protocols, psychotherapy modalities, outcome measures, safety findings, and long-term follow-up.
Results: Across the included studies, MDMA-AP produced clinically meaningful reductions in PTSD symptom severity, with full-dose MDMA (100–125 mg) consistently outperforming low-dose or active placebo comparators. Improvements were durable, with follow-up demonstrating sustained symptom reduction for up to 74 months. Safety profiles were favorable, with minimal dropout and no serious adverse events reported.
Conclusions: MDMA-assisted psychotherapy shows promising therapeutic potential for adults with TR-PTSD, yielding substantial and durable symptom reductions. Larger, multisite trials with standardized dosing, consistent psychotherapy frameworks, and rigorous safety monitoring are needed to clarify optimal treatment parameters and inform future clinical and regulatory decision making.
Objective: This scoping review’s objective is to map the clinical data surrounding MDMA-AP for TR-PTSD. Although several early-phase clinical trials have evaluated MDMA-AP, the existing evidence has not been comprehensively mapped with respect to dosing strategies, psychotherapy structure, safety, and long-term outcomes.
Methods: This scoping review followed PRISMA-ScR guidelines. A systematic search of PubMed, Embase, Cochrane Library, and ScienceDirect databases revealed studies published between January 2010 and January 2025. Eligible studies included original clinical research evaluating MDMA-AP in adults with TR-PTSD. Six studies ultimately met the inclusion criteria. Data were charted for study design, participant characteristics, dosing protocols, psychotherapy modalities, outcome measures, safety findings, and long-term follow-up.
Results: Across the included studies, MDMA-AP produced clinically meaningful reductions in PTSD symptom severity, with full-dose MDMA (100–125 mg) consistently outperforming low-dose or active placebo comparators. Improvements were durable, with follow-up demonstrating sustained symptom reduction for up to 74 months. Safety profiles were favorable, with minimal dropout and no serious adverse events reported.
Conclusions: MDMA-assisted psychotherapy shows promising therapeutic potential for adults with TR-PTSD, yielding substantial and durable symptom reductions. Larger, multisite trials with standardized dosing, consistent psychotherapy frameworks, and rigorous safety monitoring are needed to clarify optimal treatment parameters and inform future clinical and regulatory decision making.